MaxWin International Holdings Limited, an investment holding company listed on the Hong Kong Stock Exchange's GEM board (ticker: 8513.HK), manufactures and sells injection-molded plastic parts for disposable medical devices and provides tooling services; its core offerings include component parts and sub-assembly parts for applications such as respiratory products, dialysis products, blood bag products, drug delivery products, diagnostic tools, and microfluidics; it also produces plastic articles and products through subsidiaries like Inzign Pte Ltd, Medizign Pte Ltd, and P.T. Inzign.
The company operates primarily in Singapore, with manufacturing and sales extending to Asia and Europe, targeting multinational medical device corporations from the United States, Europe, and Japan. Founded in 1981 and headquartered at 16 Kallang Place, #02-10, Singapore 339156, it maintains a workforce of approximately 88-94 employees focused on production, quality assurance, engineering, and management.
Recent developments include a name change from IAG Holdings Limited to MaxWin International Holdings Limited in October 2023; disposal of its non-core amusement machines and equipment segment via sale of Savour Talent Global Limited and subsidiaries in December 2023 for HK$0.3 million to refocus on medical plastics; a share placement in July 2024 raising net proceeds of HK$9.7 million from 136 million new shares at HK$0.072 each for general working capital; board changes with appointments of executive directors such as Li Rengang in October 2024 and Yang Qijun in November 2024, alongside resignations; and a proposed 10:1 share consolidation announced in December 2025, reducing issued shares from 818 million to 81.8 million while changing the board lot size from 20,000 to 5,000 shares. In FY2024 ended December 31, revenue rose 15% to S$10.5 million with gross profit turning positive at S$0.2 million, driven by operational efficiencies, though net loss narrowed to S$2.6 million.